Protection of Rhesus Monkeys by a DNA Prime/Poxvirus Boost Malaria Vaccine Depends on Optimal DNA Priming and Inclusion of Blood Stage Antigens

Background We have previously described a four antigen malaria vaccine consisting of DNA plasmids boosted by recombinant poxviruses which protects a high percentage of rhesus monkeys against Plasmodium knowlesi (Pk) malaria. This is a multi-stage vaccine that includes two pre-erythrocytic antigens, PkCSP and PkSSP2(TRAP), and two erythrocytic antigens, PkAMA-1 and PkMSP-1(42kD). The present study reports three further experiments where we investigate the effects of DNA dose, timing, and formulation. We also compare vaccines utilizing only the pre-erythrocytic antigens with the four antigen vaccine. Methodology In three experiments, rhesus monkeys were immunized with malaria vaccines using DNA plasmid injections followed by boosting with poxvirus vaccine. A variety of parameters were tested, including formulation of DNA on poly-lactic co-glycolide (PLG) particles, varying the number of DNA injections and the amount of DNA, varying the interval between the last DNA injection to the poxvirus boost from 7 to 21 weeks, and using vaccines with from one to four malaria antigens. Monkeys were challenged with Pk sporozoites given iv 2 to 4 weeks after the poxvirus injection, and parasitemia was measured by daily Giemsa stained blood films. Immune responses in venous blood samples taken after each vaccine injection were measured by ELIspot production of interferon-γ, and by ELISA. Conclusions 1) the number of DNA injections, the formulation of the DNA plasmids, and the interval between the last DNA injection and the poxvirus injection are critical to vaccine efficacy. However, the total dose used for DNA priming is not as important; 2) the blood stage antigens PkAMA-1 and PkMSP-1 were able to protect against high parasitemias as part of a genetic vaccine where antigen folding is not well defined; 3) immunization with PkSSP2 DNA inhibited immune responses to PkCSP DNA even when vaccinations were given into separate legs; and 4) in a counter-intuitive result, higher interferon-γ ELIspot responses to the PkCSP antigen correlated with earlier appearance of parasites in the blood, despite the fact that PkCSP vaccines had a protective effect.

[1]  A. Thomas,et al.  Fine Mapping of an Epitope Recognized by an Invasion-inhibitory Monoclonal Antibody on the Malaria Vaccine Candidate Apical Membrane Antigen 1* , 2007, Journal of Biological Chemistry.

[2]  M. Sedegah,et al.  Reduced Production of RNA Transcripts from Individual DNA Plasmids Given in a Multivalent DNA Vaccine Formula , 2007, Human vaccines.

[3]  J. Lebowitz,et al.  Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42 kDa merozoite surface protein 1 (MSP1(42)) in the absence of an affinity tag. , 2006, Protein expression and purification.

[4]  K. Bojang,et al.  Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. , 2006, Vaccine.

[5]  D. Webster,et al.  A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge , 2006, Infection and Immunity.

[6]  D. Carucci,et al.  Early Gamma Interferon and Interleukin-2 Responses to Vaccination Predict the Late Resting Memory in Malaria-Naïve and Malaria-Exposed Individuals , 2006, Infection and Immunity.

[7]  J. Ulmer,et al.  Microparticle-based technologies for vaccines. , 2006, Methods.

[8]  Hong Zhou,et al.  Immunity to Recombinant Plasmodium falciparum Merozoite Surface Protein 1 (MSP1): Protection in Aotus nancymai Monkeys Strongly Correlates with Anti-MSP1 Antibody Titer and In Vitro Parasite-Inhibitory Activity , 2006, Infection and Immunity.

[9]  Zhong-Guang Zhang,et al.  Immunogenicity of C-terminus of Plasmodium falciparum merozoite surface protein 1 expressed as a non-glycosylated polypeptide in yeast. , 2006, Acta biochimica et biophysica Sinica.

[10]  V. A. Stewart,et al.  Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A. , 2006, Vaccine.

[11]  R. Sinden,et al.  Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length Plasmodium falciparum Circumsporozoite Protein , 2006, Infection and Immunity.

[12]  D. Conway,et al.  RTS,S/AS02A Malaria Vaccine Does Not Induce Parasite CSP T Cell Epitope Selection and Reduces Multiplicity of Infection , 2006, PLoS clinical trials.

[13]  Joe D. Cohen,et al.  Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. , 2006, Vaccine.

[14]  D. Webster,et al.  Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. , 2006, Vaccine.

[15]  L. Miller,et al.  Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris. , 2006, Journal of biotechnology.

[16]  Q. Bassat,et al.  Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial , 2005, The Lancet.

[17]  Aditi Gupta,et al.  Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  W. Ballou.  Malaria vaccines in development , 2005, Expert opinion on emerging drugs.

[19]  D. Carucci,et al.  Transcriptional analysis of in vivo Plasmodium yoelii liver stage gene expression. , 2005, Molecular and biochemical parasitology.

[20]  Hong Zhou,et al.  Posttranslational Modification of Recombinant Plasmodium falciparum Apical Membrane Antigen 1: Impact on Functional Immune Responses to a Malaria Vaccine Candidate , 2005, Infection and Immunity.

[21]  D. Montefiori,et al.  Enhanced Potency of Plasmid DNA Microparticle Human Immunodeficiency Virus Vaccines in Rhesus Macaques by Using a Priming-Boosting Regimen with Recombinant Proteins , 2005, Journal of Virology.

[22]  Hong Zhou,et al.  Phase 1 Clinical Trial of Apical Membrane Antigen 1: an Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria , 2005, Infection and Immunity.

[23]  S. Hoffman,et al.  Boosting of DNA Vaccine-Elicited Gamma Interferon Responses in Humans by Exposure to Malaria Parasites , 2005, Infection and Immunity.

[24]  V. Murphy,et al.  A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. , 2005, Vaccine.

[25]  D. Webster,et al.  Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Webster,et al.  Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. , 2005, The Journal of infectious diseases.

[27]  B. Ivins,et al.  CpG Oligodeoxynucleotides Adsorbed onto Polylactide-Co-Glycolide Microparticles Improve the Immunogenicity and Protective Activity of the Licensed Anthrax Vaccine , 2005, Infection and Immunity.

[28]  M. Alpers,et al.  Strain-Specific Humoral Response to a Polymorphic Malaria Vaccine , 2004, Infection and Immunity.

[29]  J. Sacci,et al.  Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF , 2004, Genes and Immunity.

[30]  Inacio Mandomando,et al.  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.

[31]  D. Carucci,et al.  Update on the clinical development of candidate malaria vaccines. , 2004, The American journal of tropical medicine and hygiene.

[32]  A. Moore,et al.  Progress in DNA‐based heterologous prime‐boost immunization strategies for malaria , 2004, Immunological reviews.

[33]  S. Hoffman,et al.  Induction in Humans of CD8+ and CD4+ T Cell and Antibody Responses by Sequential Immunization with Malaria DNA and Recombinant Protein1 , 2004, The Journal of Immunology.

[34]  W. Ballou,et al.  Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys. , 2004, The American journal of tropical medicine and hygiene.

[35]  S. Hoffman,et al.  Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. , 2004, Vaccine.

[36]  Markus S. Mueller,et al.  A Role for Apical Membrane Antigen 1 during Invasion of Hepatocytes by Plasmodium falciparum Sporozoites* , 2004, Journal of Biological Chemistry.

[37]  D. Carucci,et al.  Reduced immunogenicity of DNA vaccine plasmids in mixtures , 2004, Gene Therapy.

[38]  R. Sinden,et al.  Enhanced CD8+ T Cell Immune Responses and Protection Elicited against Plasmodium berghei Malaria by Prime Boost Immunization Regimens Using a Novel Attenuated Fowlpox Virus1 , 2004, The Journal of Immunology.

[39]  A. Saul,et al.  Progress in the development of recombinant and synthetic blood-stage malaria vaccines , 2003, Journal of Experimental Biology.

[40]  J. Yates,et al.  Exploring the proteome of Plasmodium. , 2002, International journal for parasitology.

[41]  B. Keegan,et al.  Vaccination of Monkeys with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 Confers Protection against Blood-Stage Malaria , 2002, Infection and Immunity.

[42]  Jonathan E. Allen,et al.  Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.

[43]  David L. Tabb,et al.  A proteomic view of the Plasmodium falciparum life cycle , 2002, Nature.

[44]  S. Hoffman,et al.  Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. , 2002, Human gene therapy.

[45]  S. Hoffman,et al.  Protection of Rhesus Macaques against Lethal Plasmodium knowlesi Malaria by a Heterologous DNA Priming and Poxvirus Boosting Immunization Regimen , 2002, Infection and Immunity.

[46]  S. Hoffman,et al.  Persistence of Protective Immunity to Malaria Induced by DNA Priming and Poxvirus Boosting: Characterization of Effector and Memory CD8+-T-Cell Populations , 2002, Infection and Immunity.

[47]  Thomas A. Smith,et al.  A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. , 2002, The Journal of infectious diseases.

[48]  S. Hoffman,et al.  Laser capture microdissection and molecular analysis of Plasmodium yoelii liver-stage parasites. , 2002, Molecular and biochemical parasitology.

[49]  A. Hill,et al.  Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. , 2002, Vaccine.

[50]  D. Kaslow,et al.  A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. Ulmer,et al.  Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines , 2001, Journal of Virology.

[52]  S. Hoffman,et al.  Multistage Multiantigen Heterologous Prime Boost Vaccine forPlasmodium knowlesi Malaria Provides Partial Protection in Rhesus Macaques , 2001, Infection and Immunity.

[53]  S. Hoffman,et al.  Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[54]  S. Hoffman,et al.  Improving Protective Immunity Induced by DNA-Based Immunization: Priming with Antigen and GM-CSF-Encoding Plasmid DNA and Boosting with Antigen-Expressing Recombinant Poxvirus1 2 , 2000, The Journal of Immunology.

[55]  M. Alpers,et al.  Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. , 2000, Vaccine.

[56]  J. Maguire,et al.  Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. , 2000, Vaccine.

[57]  S. Hoffman,et al.  Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Marion Becker,et al.  Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara , 1998, Nature Medicine.

[59]  S. Hoffman,et al.  Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine. , 1994, Vaccine.

[60]  M. Alpers,et al.  Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity. , 2007, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[61]  A. Hill.  Pre-erythrocytic malaria vaccines: towards greater efficacy , 2006, Nature Reviews Immunology.

[62]  U. Krzych,et al.  The dissection of CD8 T cells during liver-stage infection. , 2005, Current topics in microbiology and immunology.

[63]  D. Carucci,et al.  Functional proteome and expression analysis of sporozoites and hepatic stages of malaria development. , 2005, Current topics in microbiology and immunology.

[64]  W. Reed.  Towards an RTS,S-Based, Multi-Stage, Multi- Antigen Vaccine Against Falciparum Malaria: Progress at the Walter Reed Army Institute of Research , 2005 .

[65]  S. Hoffman,et al.  ELISPOT assay for detection of peptide specific interferon-gamma secreting cells in rhesus macaques. , 2001, Journal of immunological methods.

[66]  S. Hoffman,et al.  ELISPOT assay for detection of peptide specific Interferon-γ secreting cells in rhesus macaques , 2001 .